Shire's Vyvanse wins FDA nod as maintenance for pediatric ADHD

05/3/2013 | Medscape (free registration)

Shire obtained FDA approval to market Vyvanse, or lisdexamfetamine dimesylate, as maintenance therapy for children and teenagers with attention deficit hyperactivity disorder. This makes Vyvanse the only stimulant approved for use as a maintenance therapy in all ADHD patients older than 6, Shire says. The approval was based on data from a 32-week trial that showed lower treatment-failure rate among those who received Vyvanse.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC